Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Bimagrumab"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Donna H. Ryan
Publikováno v:
Journal of Obesity & Metabolic Syndrome, Vol 30, Iss 3, Pp 196-208 (2021)
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–#8211;pro-opiomelanocortin deficiency, proprotein c
Externí odkaz:
https://doaj.org/article/22b9f4bf26bd49b59dbad1b4b65e8c97
Autor:
Javier Durán, Manuel Estrada
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Externí odkaz:
https://doaj.org/article/3ae9941a688448b09800df2c1afbedc6
Publikováno v:
Current Treatment Options in Rheumatology. 7:63-81
Purpose of review No clinical trial in sporadic inclusion body myositis (IBM) thus far has shown a clear and sustained therapeutic effect. We review previous trial methodology, explore why results have not translated into clinical practice, and sugge
Autor:
Jens Praestgaard, Ronenn Roubenoff, Olivier Petricoul, Didier Laurent, Daniel Rooks, Michael Bartlett
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Background Bimagrumab prevents activity of myostatin and other negative regulators of skeletal muscle mass. This randomized double-blind, placebo-controlled study investigated safety, pharmacokinetics (PK), and pharmacodynamics of bimagrumab in healt
Autor:
Jens Praestgaard, Daniel Rooks, Amy Berwick, Ronenn Roubenoff, Hanns-Christian Tillmann, Michael C Steiner, Dave Singh, Michael I. Polkey, Richard Casaburi, Frits M.E. Franssen, Estelle Lach-Trifilieff
Publikováno v:
American journal of respiratory and critical care medicine, vol 199, iss 3
RationaleBimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.ObjectivesTo assess the effects of bimagrumab on skeletal muscle ma
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hani Kushlaf
Publikováno v:
Current Treatment Options in Neurology. 23
The purpose of this paper is to review the recent findings that pertain to the diagnosis and treatment of sporadic inclusion body myositis. New evidence highlighting lack of correlation between the presence of cytosolic 5′-nucleotidase 1A antibody
Autor:
Hiroyuki Nodera, Masashi Aoki, Madoka Mori-Yoshimura, Rie Teshima, Masahisa Katsuno, Satoshi Yamashita, Ken-ya Murata, Ichizo Nishino, Naoki Suzuki, Tatsumi Inamura
Publikováno v:
Rinsho Shinkeigaku. 59:806-813
A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin type II receptor antibody, improves motor function in patients with sporadic inclusion body myositis after 52 weeks' treatm
Autor:
Jens Praestgaard, Liang Kung Chen, Hidenori Arai, Olivier Petricoul, Budhaditya Goswami, Dimitris Papanicolaou, John Vissing, Yoon Sok Chung, Chris Recknor, Estelle Lach-Trifilieff, Jun Hashimoto, Laura A. Coleman, Nicolas Panchaud, Ram R. Miller, Lee Anne Filosa, Didier Laurent, Robert G. Perry, Sarah Hemsley, Charles M. Fogarty, Ola Bunte, Ronenn Roubenoff, Daniel Rooks, Therese Swan, Elisa Garcia Garayoa
Publikováno v:
Rooks, D, Swan, T, Goswami, B, Filosa, L A, Bunte, O, Panchaud, N, Coleman, L A, Miller, R R, Garcia Garayoa, E, Praestgaard, J, Perry, R G, Recknor, C, Fogarty, C M, Arai, H, Chen, L K, Hashimoto, J, Chung, Y S, Vissing, J, Laurent, D, Petricoul, O, Hemsley, S, Lach-Trifilieff, E, Papanicolaou, D A & Roubenoff, R 2020, ' Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults : A Randomized Clinical Trial ', JAMA Network Open, vol. 3, no. 10, e2020836 . https://doi.org/10.1001/jamanetworkopen.2020.20836
JAMA Netw Open
JAMA Netw Open
Importance: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. Objective: To confirm the safety and efficacy of bimagrumab plus the new s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2548e2635b4203a261b60319a8a0f71d
https://curis.ku.dk/ws/files/253352215/Bimagrumab_vs_Optimized_Standard_of_Care_for_Treatment_of_Sarcopenia.pdf
https://curis.ku.dk/ws/files/253352215/Bimagrumab_vs_Optimized_Standard_of_Care_for_Treatment_of_Sarcopenia.pdf